Identification and Description of Patients With High-risk Non Metastatic RCC

Recruiting now

Conditions studied: Renal Cell Carcinoma

In brief

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Key facts

Study ID

NCT07753343

Run by

University Hospital, Bordeaux

People needed

6109

Starts

2026-04-17

Expected to finish

2028-04-17

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients diagnosed with local RCC or high-risk locally advanced RCC,
• Included in UroCCR register between 1st january 2014 and 31st december 2023,
• Consenting to participate in UroCCR and UroCCR-Chain registers.

You may not qualify if…

• Patients with metastatic disease at inclusion,
• Patients not linked between UroCCR and SNDS datasources,
• Patients with hereditary RCC.

Where it is running

• CHU Bordeaux — Bordeaux, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.